Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- AARD
- Price
- 15.08
- Stock movement down
- -0.74 (-4.68%)
- Company name
- Aardvark Therapeutics, Inc. Common Stock
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 328.34M
- Ent value
- 299.91M
- Price/Sales
- -
- Price/Book
- 2.68
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
AARD does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 2.68 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 21.77M |
| EPS (TTM) | -2.25 |
| FCF per share (TTM) | -2.19 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -15.00K |
| Operating income (TTM) | -53.47M |
| Net income (TTM) | -48.77M |
| EPS (TTM) | -2.25 |
| EPS (1y forward) | -3.63 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 39.28M |
| Net receivables | 0.00 |
| Total current assets | 129.21M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 439.00K |
| Total assets | 133.23M |
| Accounts payable | 4.44M |
| Short/Current long term debt | 545.00K |
| Total current liabilities | 10.74M |
| Total liabilities | 10.85M |
| Shareholder's equity | 122.38M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -47.48M |
| Capital expenditures (TTM) | 101.00K |
| Free cash flow (TTM) | -47.58M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -39.85% |
| Return on Assets | -36.61% |
| Return on Invested Capital | -39.71% |
| Cash Return on Invested Capital | -38.74% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 15.94 |
| Daily high | 16.60 |
| Daily low | 14.96 |
| Daily Volume | 265K |
| All-time high | 17.41 |
| 1y analyst estimate | 32.70 |
| Beta | - |
| EPS (TTM) | -2.25 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 6 Apr 2026 |
Downside potential
Loading...
Downside potential data
| AARD | S&P500 | |
| Current price drop from All-time high | -13.38% | -0.89% |
| Highest price drop | -46.81% | -19.00% |
| Date of highest drop | 2 Dec 2025 | 8 Apr 2025 |
| Avg drop from high | -23.85% | -2.49% |
| Avg time to new high | 8 days | 6 days |
| Max time to new high | 74 days | 89 days |
COMPANY DETAILS
Marketcap
328.34M
Marketcap category
Small-cap
Description
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Employees
33
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner